Literature DB >> 12124318

Development of antitumor immune responses in reconstituted lymphopenic hosts.

Hong-Ming Hu1, Christian H Poehlein, Walter J Urba, Bernard A Fox.   

Abstract

When naïve T cells reconstitute lymphopenic hosts, they transiently proliferate and differentiate into memory-like T cells. Here we report that tumor-specific T cells preferentially expand in tumor vaccine-draining lymph nodes after a melanoma vaccine given to RAG1 mice reconstituted with naïve T cells from normal mice. The percentage of tumor-specific Tc1 T cells detected by intracellular cytokine staining was increased approximately 4-fold in reconstituted lymphopenic hosts compared with normal hosts. Concomitantly, vaccination-induced Th1 T cells were also dramatically increased in vaccinated, reconstituted RAG1 hosts. T cells derived from reconstituted RAG1 hosts exhibited a higher level of melanoma-specific cytotoxicity in vitro. These cells were significantly more potent at mediating tumor regression in vivo after adoptive transfer into mice bearing established pulmonary metastases. Vaccination is best performed concomitantly with reconstitution; delayed vaccination resulted in T cells with less therapeutic activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124318

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  Homeostatic proliferation is a barrier to transplantation tolerance.

Authors:  Zihao Wu; Steven J Bensinger; Jidong Zhang; Chuangqi Chen; Xueli Yuan; Xiaolun Huang; James F Markmann; Alireza Kassaee; Bruce R Rosengard; Wayne W Hancock; Mohamed H Sayegh; Laurence A Turka
Journal:  Nat Med       Date:  2003-11-30       Impact factor: 53.440

Review 2.  Making room for T cells.

Authors:  Gabriel N Maine; James J Mulé
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.

Authors:  Shawn M Jensen; Christopher G Twitty; Levi D Maston; Paul A Antony; May Lim; Hong-Ming Hu; Ulf Petrausch; Nicholas P Restifo; Bernard A Fox
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

4.  Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice.

Authors:  Robert G Newman; Michael J Dee; Thomas R Malek; Eckhard R Podack; Robert B Levy
Journal:  Blood       Date:  2014-03-31       Impact factor: 22.113

Review 5.  Innate memory T cells.

Authors:  Stephen C Jameson; You Jeong Lee; Kristin A Hogquist
Journal:  Adv Immunol       Date:  2015-02-07       Impact factor: 3.543

6.  Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples.

Authors:  Daniel J Powell; Linda L Parker; Steven A Rosenberg
Journal:  J Immunother       Date:  2005 Jul-Aug       Impact factor: 4.456

7.  To ablate or not to ablate? HSCs in the T cell driver's seat.

Authors:  Claudio Anasetti; James J Mulé
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

Review 8.  Chemotherapy and tumor immunity: an unexpected collaboration.

Authors:  Leisha A Emens
Journal:  Front Biosci       Date:  2008-01-01

9.  Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.

Authors:  Michael G LaCelle; Shawn M Jensen; Bernard A Fox
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

10.  Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence.

Authors:  Brian M Olson; Douglas G McNeel
Journal:  Expert Rev Vaccines       Date:  2012-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.